Adagio Medical Holdings Inc
ADGM
View Detailed Chart
1.130USD
-0.110-8.87%
Market hours （ET）Quotes delayed by 15 min
15.13MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-8.87%
5 Days
0.00%
1 Month
+13.00%
6 Months
-44.06%
Year to Date
+8.65%
1 Year
+20.23%
View Detailed Chart
TradingKey Stock Score of Adagio Medical Holdings Inc
Currency: USD Updated: 2026-03-27Key Insights
Adagio Medical Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Adagio Medical Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Adagio Medical Holdings Inc Highlights
StrengthsRisks
Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Fairly Valued
The company’s latest PE is -0.81, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.35M shares, increasing 14.80% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 79.45K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.000
Target Price
+222.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Adagio Medical Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Adagio Medical Holdings Inc Info
Adagio Medical Holdings, Inc. is a commercial stage medical device company. It is focused on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia. It is developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for the treatment of ventricular arrhythmia.
Ticker SymbolADGM
CompanyAdagio Medical Holdings Inc
CEOUsen (Todd)
Website
Related Instruments
+0.26%
+0.06%
+1.63%
+0.84%
-0.49%
-1.52%
-0.29%
-2.72%
+0.03%
-7.86%
-0.97%
-1.23%
-3.82%
-1.16%
-0.18%
-1.98%
+1.69%
-0.19%
-0.75%
-1.39%Popular Symbols
246.576
-6.314 (-2.50%)
167.700
+0.180 (+0.11%)
67635.420
+1051.370 (+1.58%)
258.695
-16.645 (-6.05%)
2067.500
+67.500 (+3.38%)
363.910
+2.080 (+0.57%)
4538.370
+45.850 (+1.02%)
101.692
+1.083 (+1.08%)
1.145
-0.005 (-0.47%)
159.585
-0.667 (-0.42%)
